Nonselective pan-HDAC inhibitors, for example, and specific class I HDAC inhibitors, fro example, romidepsin, have shown significant anti-multiple myeloma activity in preclinical models (38). The gene discussed is HDAC9; the disease is plasma cell myeloma.